New hope for CF patients who Can't use current drugs
Disease control
Recruiting now
This study is testing a new inhaled medication called ARCT-032 for adults with cystic fibrosis who cannot use standard CFTR modulator drugs. Participants will use the inhaler daily for 4 weeks while researchers monitor safety and check if it improves lung function and quality of …
Phase: PHASE2 • Sponsor: Arcturus Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC